{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:14:24Z","timestamp":1761560064512,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107921","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T21:54:22Z","timestamp":1625262862000},"page":"107921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy of bevacizumab in the treatment of pterygium: An updated meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"98","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiangqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107921_b0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.17116\/oftalma2017133576-83","article-title":"Pterygium: etiology, pathogenesis, treatment","volume":"133","author":"Malozhen","year":"2017","journal-title":"Vestnik Oftalmologii"},{"key":"10.1016\/j.intimp.2021.107921_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sjopt.2016.02.007","article-title":"High frequency of squamous intraepithelial neoplasia in pterygium related to low ultraviolet light exposure","volume":"30","author":"Zoroquiain","year":"2016","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213956","article-title":"Impact of pterygium on the ocular surface and meibomian glands","volume":"14","author":"Wanzeler","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107921_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.17116\/oftalma2018134185-88","article-title":"Surgical treatment of pterygium","volume":"134","author":"Petrayevsky","year":"2018","journal-title":"Vestnik Oftalmologii"},{"key":"10.1016\/j.intimp.2021.107921_b0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4314\/ahs.v14i1.11","article-title":"Young patient's age determines pterygium recurrence after surgery","volume":"14","author":"Anguria","year":"2014","journal-title":"Afr. Health Sci."},{"key":"10.1016\/j.intimp.2021.107921_b0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000210444","article-title":"Long-term results of bare sclera, limbal-conjunctival autograft and amniotic membrane graft techniques in primary pterygium excisions","volume":"223","author":"Ozer","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.intimp.2021.107921_b0035","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.12659\/MSM.915629","article-title":"A Retrospective Study to Compare the Recurrence Rate After Treatment of Pterygium by Conjunctival Autograft, Primary Closure, and Amniotic Membrane Transplantation","volume":"25","author":"R\u00f6ck","year":"2019","journal-title":"Med. Sci. Monitor"},{"key":"10.1016\/j.intimp.2021.107921_b0040","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2147\/OPTH.S186543","article-title":"How to minimize pterygium recurrence rates: clinical perspectives","volume":"12","author":"Nuzzi","year":"2018","journal-title":"Clin. Ophthalmol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2021.107921_b0045","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/ICO.0000000000001744","article-title":"The Evolving Story of Pterygium","volume":"37","author":"Young","year":"2018","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2021.107921_b0050","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s10792-018-01069-2","article-title":"Metabolomics analysis in pterygium tissue","volume":"39","author":"Saglik","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5935\/0004-2749.20170068","article-title":"An investigation of human beta-defensins and cathelicidin expression in patients with pterygium","volume":"80","author":"Karadag","year":"2017","journal-title":"Arq Bras Oftalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/08820538.2014.971822","article-title":"Molecular Basis of Pterygium Development","volume":"31","author":"C\u00e1rdenas-Cant\u00fa","year":"2016","journal-title":"Semin Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0065","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1038\/s41598-017-07844-y","article-title":"mTORC1 regulates apoptosis and cell proliferation in pterygium via targeting autophagy and FGFR3","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.107921_b0070","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5935\/0004-2749.20190103","article-title":"Mechanisms and biomarker candidates in pterygium development","volume":"82","author":"Wanzeler","year":"2019","journal-title":"Arq Bras Oftalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0075","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.intimp.2021.107921_b0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/aos.13178","article-title":"Use of anti-vascular endothelial growth factor in the management of pterygium","volume":"95","author":"Mak","year":"2017","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.intimp.2021.107921_b0085","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/eye.2016.29","article-title":"5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium","volume":"30","author":"Bekibele","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.intimp.2021.107921_b0090","first-page":"483","article-title":"The use of Bevacizumab with corneal limbal stem cell autograft for management of recurrent pterygium","volume":"30","author":"Chen","year":"2012","journal-title":"Chinese J. Pract. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3341\/kjo.2015.29.6.375","article-title":"A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery","volume":"29","author":"Hwang","year":"2015","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0100","first-page":"512","article-title":"Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?","volume":"7","author":"Karalezli","year":"2014","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0105","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.clinthera.2015.08.023","article-title":"Prevention of recurrent pterygium with topical bevacizumab 0.05% eye drops: a randomized controlled trial","volume":"37","author":"Kasetsuwan","year":"2015","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.intimp.2021.107921_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6824670","article-title":"Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence","author":"Nuzzi","year":"2017","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0115","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/ICO.0b013e3182772d4e","article-title":"Topical application of bevacizumab as an adjunct to recurrent pterygium surgery","volume":"32","author":"Ozgurhan","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2021.107921_b0120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4103\/0301-4738.120220","article-title":"Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence","volume":"62","author":"Ozsutcu","year":"2014","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.intimp.2021.107921_b0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3928\/15428877-20120802-02","article-title":"Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report","volume":"43","author":"Shahin","year":"2012","journal-title":"Ophthalmic Surg. Lasers Imag."},{"key":"10.1016\/j.intimp.2021.107921_b0135","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e31820ca63f","article-title":"Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial","volume":"30","author":"Shenasi","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2021.107921_b0140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4103\/0301-4738.171508","article-title":"A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients","volume":"63","author":"Singh","year":"2015","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0145","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00417-020-04704-w","article-title":"Efficacy of bevacizumab injection after pterygium excision and limbal conjunctival autograft with limbal fixation suture","volume":"258","author":"Yang","year":"2020","journal-title":"Graefes Archive Clin. Experim. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0150","first-page":"56","article-title":"Study on the short-term and long-term effects of different drug-administered amniotic membrane transplantation for pterygium","volume":"27","author":"Chen","year":"2019","journal-title":"J. Clin. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0155","first-page":"2532","article-title":"Comparative study of pterygium surgery combined with bevacizumab or mitomycin C","author":"Xu","year":"2013","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0160","first-page":"754","article-title":"The application and effect of Bevacizumab in pterygium surgery","volume":"16","author":"Zhang","year":"2014","journal-title":"Chinese J. Optometry Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.intimp.2021.107921_b0165","first-page":"1833","article-title":"Clinical research of Avastin in treatment of recurrent pterygium","volume":"11","author":"Kuang","year":"2011","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0161-6420(94)31270-X","article-title":"Pterygium recurrence time","volume":"101","author":"Hirst","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.intimp.2021.107921_b0175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtos.2014.01.001","article-title":"Surgical management of pterygium","volume":"12","author":"Janson","year":"2014","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.intimp.2021.107921_b0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/ICO.0000000000000037","article-title":"Bevacizumab in the treatment of pterygium: a meta-analysis","volume":"33","author":"Hu","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2021.107921_b0185","doi-asserted-by":"crossref","first-page":"4598173","DOI":"10.1155\/2018\/4598173","article-title":"Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12886-017-0601-5","article-title":"Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis","volume":"17","author":"Zeng","year":"2017","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.intimp.2021.107921_b0195","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000503636","article-title":"The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance","volume":"63","author":"Liu","year":"2020","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.intimp.2021.107921_b0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1515\/rjim-2015-0027","article-title":"VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature","volume":"53","author":"Costache","year":"2015","journal-title":"Romanian J. Internal Med."},{"key":"10.1016\/j.intimp.2021.107921_b0205","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/ICO.0000000000001213","article-title":"Expression of Peroxiredoxin 2 and Vascular Endothelial Growth Factor Receptor 2 in Pterygium","volume":"36","author":"Wang","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2021.107921_b0210","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/eye.2012.194","article-title":"Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium","volume":"26","author":"Ling","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.intimp.2021.107921_b0215","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3892\/ijmm.2016.2647","article-title":"Regulation of vascular endothelial growth factor-C by tumor necrosis factor-\u03b1 in the conjunctiva and pterygium","volume":"38","author":"Dong","year":"2016","journal-title":"Int. J. Mol. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:26:42Z","timestamp":1747308402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921005579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"alternative-id":["S1567576921005579"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107921","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of bevacizumab in the treatment of pterygium: An updated meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107921"}}